Alliances
Acceleron Pharma plans to seek regulatory approval next year for its investigational drug luspatercept. The treatment hit its Phase III endpoints.
Cambridge, Massachusetts-based Biogen exercised its option to acquire additional shares of Samsung Bioepis, a joint venture with Samsung BioLogics that was founded in 2012.
AbbVie Ventures, the investment arm of AbbVie, led a $53 million Series A funding round for Carisma Therapeutics and its immunotherapy CAR-Macrophage platform.
Nearly four years after first forging a research collaboration, AbbVie and Calico, Google’s life science company, have extended that 10-year pact with another $1 billion pledge to develop therapies associated with age-related diseases, including neurodegeneration and cancer.
The Dementia Discovery Fund (DDF), a venture capital fund focused solely on dementia-related investments, completed $350 million of fundraising. The initial target was $200 million.
This morning two companies announced deals that will yield potential benefits to multiple patient populations.
AbbVie is taking another shot at solid tumor treatments through a collaboration with Calibr.
Poietis along with Prometheus, a division of Skeletal Tissue Engineering at Leuven, Belgium, announced they had entered into a two-year Collaborative Research Agreement to develop high-precision 3D Bioprinting.
New York-based Kallyope and Danish company Novo Nordisk A/S signed a research collaboration and option deal to discover novel therapeutics to treat obesity and diabetes.
June is Alzheimer’s & Brain Awareness Month and June 21 is dubbed “The Longest Day,” which focuses on raising awareness of Alzheimer’s disease.
PRESS RELEASES